Enanta Pharmaceuticals (ENTA) stock surged 6.7% due to positive feedback on lead candidate

From Nasdaq: 2024-07-15 10:10:00

Enanta Pharmaceuticals (ENTA) shares surged 6.7% to $16 in the last session due to increased trading volume. The company’s lead candidate, zelicapavir, is showing promise in treating respiratory syncytial virus. Analysts predict a quarterly loss of $1.49 per share with revenues of $17.3 million, highlighting the importance of earnings estimates in stock performance.

Ardelyx (ARDX) also saw a 1.2% increase in shares, closing at $5.89. The company’s upcoming EPS estimate has increased 8.8% to -$0.10, but is down 25% from last year. With a Zacks Rank #3 (Hold), Ardelyx remains a stock to watch in the Medical – Drugs industry. Stay informed for potential future developments.

Make informed investment decisions by following Zacks Investment Research for the latest stock recommendations. Both Enanta Pharmaceuticals and Ardelyx offer free stock analysis reports on Zacks.com. Keep track of industry trends and stock updates to stay ahead in your investment strategies. Stay informed and make the most of your investments with Zacks Investment Research.



Read more at Nasdaq: Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock?